A routine court case was intended to force generic drug developers into settlements. Instead, Harmony Biosciences finds itself in a slugfest at the worst possible time.

I haven't found a reason for shares to lose over 20% of their value in a few days, but the business is healthy and Wakix has considerable commercial momentum. Full-year 2025 earnings are scheduled for next week, so I'll soon learn if there are any negative surprises or if this Opportunistic investment pays off.

This month's digest recaps the J.P. Morgan Healthcare Conference and previews the upcoming earnings season for Q4 2025.

This month I explore the recent surge in M&A activity, where 2025 ranks from a historical perspective, and evaluate the acquisition potential of the coverage ecosystem.

The business is objectively strong based on profitability and cash flow, but analysts remain concerned about potential commercial headwinds in the next few years.

A look at what to expect when companies report third-quarter 2025 operating results beginning in late October and extending through November.

This month I share insights into how I might temporarily downsize or exit Finch Trades positions if the market keeps melting up.

Management didn't share data, but said a higher than expected response rate in the placebo group derailed the study.

Shares are expected to move by double digits in either direction pending results. Let's scope out the possibilities and what might happen next for maximum preparedness.

Revenue grew just 16% from the prior-year period, although commercial momentum metrics suggest a rebound is likely. Meanwhile, the business could generate over $250 million in operating cash flow this year.

A look at what to expect when companies report second-quarter 2025 operating results beginning in late July and extending through August.

No matter how investors slice it, Wakix is dominating the commercial landscape in narcolepsy treatments. In fact, it's been responsible for over two-thirds of the overall market's growth since launching in 2019.

The business is rock solid, but both generic and next-generation competition are on the horizon. Meanwhile, a key data readout in Q3 2025 might have a higher probability of success than analysts think.

This is the final short-term investment for Q1 2025 earnings season. As with the others, I'm targeting a return of at least 10%. What characteristics have I looked for?

A look at what to expect when companies report first-quarter 2025 operating results beginning in late April and extending through May.